Click Here for 5% Off Your First Aladdin Purchase!
Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

FAK Antibody - Primary antibody, specific to FAK, Rabbit IgG

  • Azide Free
  • Carrier Free
  • ExactAb™
  • Validated
  • Lot by Lot
Features and benefits
  • Short Overview:

    pAb; Rabbit anti Human FAK Antibody; WB, IHC; Unconjugated

  • Species reactivity(Reacts with): Human,Mouse,Rat
  • Isotype: Rabbit IgG
    Application:
  • IHC
  • WB
Item Number
Ab102794
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab102794-10μl
10μl
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$49.90
Ab102794-20μl
20μl
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$754.90
Ab102794-50μl
50μl
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$149.90
Ab102794-100μl
100μl
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$249.90
Ab102794-1ml
1ml
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,999.90
Add to Wish List Compare
Bulk Order  DATASHEET

pAb; Rabbit anti Human FAK Antibody; WB, IHC; Unconjugated

View related series
Accession#:Q05397 FAK Gene ID:5747 PTK2

Basic Description

Product NameFAK Antibody - Primary antibody, specific to FAK, Rabbit IgG
SynonymsFADK 1 antibody; FADK antibody; FAK related non kinase polypeptide antibody; FAK1 antibody; FAK1_HUMAN antibody; Focal adhesion kinase 1 antibody; Focal adhesion Kinase antibody; Focal adhesion kinase isoform FAK Del33 antibody; Focal adhesion kinase rela
Specifications & PurityExactAb™, Validated, Carrier Free, Azide Free, Lot by Lot
Host speciesRabbit
SpecificityFAK
ImmunogenRecombinant FAK expressed in E.coli (AA 798-1041)
Positive ControlWB: C6, NIH/3T3, K562, HUVEC and MCF7 cell lysates. IHC: Human Liver tissue, Human Thyroid tissue, Human Liver cancer tissue.
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Validated
Product Description

Rabbit anti Human FAK Antibody, Polyclonal, could be used for WB, IHC and so on.
Application
WB: 0.5-2 µg/mL
IHC: 5-20 µg/mL
Protein Function
Non-receptor protein-tyrosine kinase implicated in signaling pathways involved in cell motility, proliferation and apoptosis. Activated by tyrosine-phosphorylation in response to either integrin clustering induced by cell adhesion or antibody cross-linking, or via G-protein coupled receptor (GPCR) occupancy by ligands such as bombesin or lysophosphatidic acid, or via LDL receptor occupancy. Microtubule-induced dephosphorylation at Tyr-397 is crucial for the induction of focal adhesion disassembly. Plays a potential role in oncogenic transformations resulting in increased kinase activity.

Product Properties

IsotypeRabbit IgG
SDS-PAGE150 kDa
Purification MethodAntigen affinity purified and Protein A purified
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -20°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at 4℃ short term (1-2 weeks). Store at -20℃ long term (24 months). Upon delivery aliquot. Avoid freeze/thaw cycle.

Images

FAK Antibody (Ab102794) - Western Blot
All lanes: FAK Antibody (Ab102794) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution

Predicted band size: 125 kDa
Observed band size: 111 kDa
Exposure time: 15.6 s

FAK Antibody (Ab102794) - Western Blot
All lanes: FAK Antibody (Ab102794) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution

Predicted band size: 125 kDa
Observed band size: 111 kDa
Exposure time: 15.6 s

FAK Antibody (Ab102794) - IHC
DAB staining on IHC
Samples: Human Liver Tissue
Primary Ab: 20 µg/mL FAK Antibody (Ab102794)
Second Ab: 2 µg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody.

FAK Antibody (Ab102794) - IHC
DAB staining on IHC
Samples: Human Thyroid Tissue
Primary Ab: 20 µg/mL FAK Antibody (Ab102794)
Second Ab: 2 µg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody.

FAK Antibody (Ab102794) - IHC
DAB staining on IHC
Samples: Human Liver cancer Tissue
Primary Ab: 20 µg/mL FAK Antibody (Ab102794)
Second Ab: 2 µg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody.

Associated Targets

PTK2 Tclin Focal adhesion kinase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Application

ApplicationDilution info
IHC

5-20 µg/mL

WB

0.5-2 µg/mL

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

2 results found

Lot NumberCertificate TypeDateItem
ZJ23F0901165Certificate of AnalysisSep 28, 2023 Ab102794
ZJ23F0901164Certificate of AnalysisSep 28, 2023 Ab102794

Related Documents

 SDS

 Specification Sheet

FAQs and Articles

FAQ
Immunohistochemical staining protocol for frozen samples (IHC-Fr)
Categories: Protocols
Tags:
IHC Monoclonal antibodies Immunohistochemistry Frozen section Recombinant Antibodies
Immunohistochemistry (IHC) staining antigen retrieval protocol
Categories: Protocols
Tags:
IHC Monoclonal antibodies Immunohistochemistry Recombinant Antibodies Antigen Retrieval
Immunopeptide blocking assay
Categories: Protocols
Tags:
Immunopeptideblocking PolyclonalAntibody SpecificBinding

References

1. Nowakowski J, Cronin CN, McRee DE, Knuth MW, Nelson CG, Pavletich NP, Rogers J, Sang BC, Scheibe DN, Swanson RV et al..  (2002)  Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography..  Structure,  10  (12): (1659-67).  [PMID:12467573]
2. Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S et al..  (2012)  7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes..  J Med Chem,  55  (1): (403-13).  [PMID:22136433]
3. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C et al..  (2007)  Patterns of somatic mutation in human cancer genomes..  Nature,  446  (7132): (153-8).  [PMID:17344846]
4. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM et al..  (2004)  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays..  J Med Chem,  47  (27): (6658-61).  [PMID:15615512]
5. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M et al..  (2009)  Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells..  Leukemia,  23  (3): (477-85).  [PMID:19039322]
6. Le Romancer M, Treilleux I, Leconte N, Robin-Lespinasse Y, Sentis S, Bouchekioua-Bouzaghou K, Goddard S, Gobert-Gosse S, Corbo L.  (2008)  Regulation of estrogen rapid signaling through arginine methylation by PRMT1..  Mol Cell,  31  (2): (212-21).  [PMID:18657504]
7. Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, Cui JJ, Deal JG, Deng YL, Dinh D et al..  (2014)  Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations..  J Med Chem,  57  (11): (4720-44).  [PMID:24819116]
8. Oyarzabal J, Zarich N, Albarran MI, Palacios I, Urbano-Cuadrado M, Mateos G, Reymundo I, Rabal O, Salgado A, Corrionero A et al..  (2010)  Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach..  J Med Chem,  53  (18): (6618-28).  [PMID:20722422]
9. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H et al..  (2011)  Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase..  J Med Chem,  54  (20): (7066-83).  [PMID:21936542]
10. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q et al..  (2009)  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)..  Blood,  114  (14): (2984-92).  [PMID:19654408]
11. Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA, Hunt JT, Rawlins DB, Shan W, Ahmed SZ et al..  (2004)  N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent..  J Med Chem,  47  (7): (1719-28).  [PMID:15027863]
12. Lee SL, Hsu EC, Chou CC, Chuang HC, Bai LY, Kulp SK, Chen CS.  (2011)  Identification and characterization of a novel integrin-linked kinase inhibitor..  J Med Chem,  54  (18): (6364-74).  [PMID:21823616]
13. Weinberg LR, Albom MS, Angeles TS, Husten J, Lisko JG, McHugh RJ, Milkiewicz KL, Murthy S, Ott GR, Theroff JP et al..  (2011)  Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors..  Bioorg Med Chem Lett,  21  (1): (164-7).  [PMID:21123062]
14. Milkiewicz KL, Aimone LD, Albom MS, Angeles TS, Chang H, Grobelny JV, Husten J, Losardo C, Miknyoczki S, Murthy S et al..  (2011)  Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group..  Bioorg Med Chem,  19  (21): (6274-84).  [PMID:21967808]
15. Ott GR, Tripathy R, Cheng M, McHugh R, Anzalone AV, Underiner TL, Curry MA, Quail MR, Lu L, Wan W et al..  (2010)  Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity..  ACS Med Chem Lett,  1  (9): (493-8).  [PMID:24900237]
16. Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D'Anello M et al..  (2015)  Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy..  J Med Chem,  58  (17): (6875-98).  [PMID:26222319]
17. Tanjoni I, Walsh C, Uryu S, Tomar A, Nam JO, Mielgo A, Lim ST, Liang C, Koenig M, Sun C et al..  (2010)  PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments..  Cancer Biol Ther,  9  (10): (764-77).  [PMID:20234191]
18. Li B, Cociorva OM, Nomanbhoy T, Weissig H, Li Q, Nakamura K, Liyanage M, Zhang MC, Shih AY, Aban A et al..  (2013)  Hit-to-lead optimization and kinase selectivity of imidazo[1,2-a]quinoxalin-4-amine derived JNK1 inhibitors..  Bioorg Med Chem Lett,  23  (18): (5217-22).  [PMID:23916259]
19. Fraser C, Dawson JC, Dowling R, Houston DR, Weiss JT, Munro AF, Muir M, Harrington L, Webster SP, Frame MC et al..  (2016)  Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase..  J Med Chem,  59  (10): (4697-710).  [PMID:27115835]
20. George DM, Breinlinger EC, Friedman M, Zhang Y, Wang J, Argiriadi M, Bansal-Pakala P, Barth M, Duignan DB, Honore P et al..  (2015)  Discovery of selective and orally bioavailable protein kinase Cθ (PKCθ) inhibitors from a fragment hit..  J Med Chem,  58  (1): (222-36).  [PMID:25000588]
21. Aronov AM, Tang Q, Martinez-Botella G, Bemis GW, Cao J, Chen G, Ewing NP, Ford PJ, Germann UA, Green J et al..  (2009)  Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control..  J Med Chem,  52  (20): (6362-8).  [PMID:19827834]
22. Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, Ohmori O, Bigner DD, Friedman HS, Rich JN.  (2007)  A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth..  Mol Carcinog,  46  (6): (488-96).  [PMID:17219439]
23. Kim KH, Maderna A, Schnute ME, Hegen M, Mohan S, Miyashiro J, Lin L, Li E, Keegan S, Lussier J et al..  (2011)  Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis..  Bioorg Med Chem Lett,  21  (21): (6258-63).  [PMID:21958547]
24. Lam B, Arikawa Y, Cramlett J, Dong Q, de Jong R, Feher V, Grimshaw CE, Farrell PJ, Hoffman ID, Jennings A et al..  (2016)  Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)..  Bioorg Med Chem Lett,  26  (24): (5947-5950).  [PMID:27839918]
25. Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, Ding Y, Tamez V, Zhang Y, Mathur M et al..  (2015)  Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies..  J Med Chem,  58  (21): (8373-86).  [PMID:26505898]
26. Li Y, Xiong Y, Zhang G, Zhang L, Yang W, Yang J, Huang L, Qiao Z, Miao Z, Lin G et al..  (2018)  Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model..  J Med Chem,  61  (24): (11398-11414).  [PMID:30480444]
27. Powell CE, Gao Y, Tan L, Donovan KA, Nowak RP, Loehr A, Bahcall M, Fischer ES, Jänne PA, George RE et al..  (2018)  Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)..  J Med Chem,  61  (9): (4249-4255).  [PMID:29660984]
28. Czako B, Marszalek JR, Burke JP, Mandal P, Leonard PG, Cross JB, Mseeh F, Jiang Y, Chang EQ, Suzuki E et al..  (2020)  Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R..  J Med Chem,  129  (3): (589-97).  [PMID:32787110]
29. Seunghee Hong,Jinhee Kim,Sun-Mi Yun,Hyunseung Lee,Yoonsu Park,Soon-Sun Hong,Sungwoo Hong.  (2013-04-23)  Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant..  Journal of medicinal chemistry,  56  ((9)): (3531-3545).  [PMID:23600806]
30. Sharon Gauci,Andreas O Helbig,Monique Slijper,Jeroen Krijgsveld,Albert J R Heck,Shabaz Mohammed.  (2009-05-06)  Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach..  Analytical chemistry,  81  ((11)): (4493-4501).  [PMID:19413330]
31. Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, Serchi T, Orlandini M, Bernardini G, Caradonna NP, Spallarossa A, Brullo C, Schenone S, Bruno O, Ranise A, Bondavalli F, Hoffmann O, Bologna M, Angelucci A, Botta M..  (2007)  Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice..  J Med Chem,  50  (23): (5579-5588).  [PMID:17929792]
32. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J..  (2007)  Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling..  Proc Natl Acad Sci U S A,  104  (50): (19936-19941).  [PMID:18077425]
33. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parsons JT..  (2007)  Cellular characterization of a novel focal adhesion kinase inhibitor..  J Biol Chem,  282  (20): (14845-14852).  [PMID:17395594]
34. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P..  (2008)  Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors..  J Med Chem,  51  (21): (6642-6645).  [PMID:18834107]
35. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, Cance WG..  (2008)  A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth..  J Med Chem,  51  (23): (7405-7416).  [PMID:18989950]
36. Li R, Pourpak A, Morris SW..  (2009)  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach..  J Med Chem,  52  (16): (4981-5004).  [PMID:19610618]
37. Shomin CD, Meyer SC, Ghosh I..  (2009)  Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling..  Bioorg Med Chem,  17  (17): (6196-6202).  [PMID:19674907]
38. Wee XK, Yeo WK, Zhang B, Tan VB, Lim KM, Tay TE, Go ML..  (2009)  Synthesis and evaluation of functionalized isoindigos as antiproliferative agents..  Bioorg Med Chem,  17  (21): (7562-7571).  [PMID:19783149]
39. Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD..  (2009)  Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors..  Bioorg Med Chem Lett,  19  (21): (6122-6126).  [PMID:19783434]
40. Lesuisse D, Dutruc-Rosset G, Tiraboschi G, Dreyer MK, Maignan S, Chevalier A, Halley F, Bertrand P, Burgevin MC, Quarteronet D, Rooney T..  (2010)  Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2..  Bioorg Med Chem Lett,  20  (6): (1985-1989).  [PMID:20167481]
41. Deng X, Lim SM, Zhang J, Gray NS..  (2010)  Broad spectrum alkynyl inhibitors of T315I Bcr-Abl..  Bioorg Med Chem Lett,  20  (14): (4196-4200).  [PMID:20541934]
42. Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, Tóth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I..  (2011)  Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration..  Bioorg Med Chem Lett,  21  (1): (315-319).  [PMID:21112785]
43. Kim MH, Kim M, Yu H, Kim H, Yoo KH, Sim T, Hah JM..  (2011)  Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells..  Bioorg Med Chem,  19  (6): (1915-1923).  [PMID:21353571]
44. Lesuisse D, Mauger J, Nemecek C, Maignan S, Boiziau J, Harlow G, Hittinger A, Ruf S, Strobel H, Nair A, Ritter K, Malleron JL, Dagallier A, El-Ahmad Y, Guilloteau JP, Guizani H, Bouchard H, Venot C..  (2011)  Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors..  Bioorg Med Chem Lett,  21  (8): (2224-2228).  [PMID:21441024]
45. Charrier JD, Miller A, Kay DP, Brenchley G, Twin HC, Collier PN, Ramaya S, Keily SB, Durrant SJ, Knegtel RM, Tanner AJ, Brown K, Curnock AP, Jimenez JM..  (2011)  Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors..  J Med Chem,  54  (7): (2341-2350).  [PMID:21391610]
46. Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R, Birtwistle JS, Kaluarachchi KK, Chen X, Bast RC, Liao WS, McMurray JS..  (2011)  Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3..  J Med Chem,  54  (10): (3549-3563).  [PMID:21486047]
47. Walker DP, Zawistoski MP, McGlynn MA, Li JC, Kung DW, Bonnette PC, Baumann A, Buckbinder L, Houser JA, Boer J, Mistry A, Han S, Xing L, Guzman-Perez A..  (2009)  Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity..  Bioorg Med Chem Lett,  19  (12): (3253-3258).  [PMID:19428251]
48. Ebada SS, Schulz B, Wray V, Totzke F, Kubbutat MH, Müller WE, Hamacher A, Kassack MU, Lin W, Proksch P..  (2011)  Arthrinins A-D: novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp..  Bioorg Med Chem,  19  (15): (4644-4651).  [PMID:21741249]
49. Radi M, Brullo C, Crespan E, Tintori C, Musumeci F, Biava M, Schenone S, Dreassi E, Zamperini C, Maga G, Pagano D, Angelucci A, Bologna M, Botta M..  (2011)  Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells..  Bioorg Med Chem Lett,  21  (19): (5928-5933).  [PMID:21856155]
50. Wang F, Li J, Sinn AL, Knabe WE, Khanna M, Jo I, Silver JM, Oh K, Li L, Sandusky GE, Sledge GW, Nakshatri H, Jones DR, Pollok KE, Meroueh SO..  (2011)  Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis..  J Med Chem,  54  (20): (7193-7205).  [PMID:21851064]
51. Kim H, Kim M, Lee J, Yu H, Hah JM..  (2011)  Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells..  Bioorg Med Chem,  19  (22): (6760-6767).  [PMID:22014755]
52. Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Yano J, Aertgeerts K, Kamiyama K..  (2011)  Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold..  J Med Chem,  54  (23): (8030-8050).  [PMID:22003817]
53. Bijian K, Zhang Z, Xu B, Jie S, Chen B, Wan S, Wu J, Jiang T, Alaoui-Jamali MA..  (2012)  Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases..  Eur J Med Chem,  48  (143-152).  [PMID:22204902]
54. Cuny GD, Ulyanova NP, Patnaik D, Liu JF, Lin X, Auerbach K, Ray SS, Xian J, Glicksman MA, Stein RL, Higgins JM..  (2012)  Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors..  Bioorg Med Chem Lett,  22  (5): (2015-2019).  [PMID:22335895]
55. Martínez González S, Hernández AI, Varela C, Rodríguez-Arístegui S, Lorenzo M, Rodríguez A, Rivero V, Martín JI, Saluste CG, Ramos-Lima F, Cendón E, Cebrián D, Aguirre E, Gomez-Casero E, Albarrán M, Alfonso P, García-Serelde B, Oyarzabal J, Rabal O, Mulero F, Gonzalez-Granda T, Link W, Fominaya J, Barbacid M, Bischoff JR, Pizcueta P, Pastor J..  (2012)  Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor..  Bioorg Med Chem Lett,  22  (10): (3460-3466).  [PMID:22520259]
56. Sunose M, Bell K, Ellard K, Bergamini G, Neubauer G, Werner T, Ramsden N..  (2012)  Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease..  Bioorg Med Chem Lett,  22  (14): (4613-4618).  [PMID:22726925]
57. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, Gray NS..  (2012)  GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor..  Bioorg Med Chem Lett,  22  (17): (5625-5629).  [PMID:22863203]
58. Mortensen DS, Sapienza J, Lee BG, Perrin-Ninkovic SM, Harris R, Shevlin G, Parnes JS, Whitefield B, Hickman M, Khambatta G, Bisonette RR, Peng S, Gamez JC, Leisten J, Narla RK, Fultz KE, Sankar S..  (2013)  Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase..  Bioorg Med Chem Lett,  23  (6): (1588-1591).  [PMID:23414803]
59. More SV, Chang TT, Chiao YP, Jao SC, Lu CK, Li WS..  (2013)  Glycosylation enhances the anti-migratory activities of isomalyngamide A analogs..  Eur J Med Chem,  64  (169-178).  [PMID:23644200]
60. Bowers S, Truong AP, Ye M, Aubele DL, Sealy JM, Neitz RJ, Hom RK, Chan W, Dappen MS, Galemmo RA, Konradi AW, Sham HL, Zhu YL, Beroza P, Tonn G, Zhang H, Hoffman J, Motter R, Fauss D, Tanaka P, Bova MP, Ren Z, Tam D, Ruslim L, Baker J, Pandya D, Diep L, Fitzgerald K, Artis DR, Anderson JP, Bergeron M..  (2013)  Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors..  Bioorg Med Chem Lett,  23  (9): (2743-2749).  [PMID:23522834]
61. Zhao H, Caflisch A..  (2014)  Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk..  Bioorg Med Chem Lett,  24  (6): (1523-1527).  [PMID:24569110]
62. Gogate PN, Ethirajan M, Kurenova EV, Magis AT, Pandey RK, Cance WG..  (2014)  Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction..  Eur J Med Chem,  80  (154-166).  [PMID:24780592]
63. Blake JF, Gaudino JJ, De Meese J, Mohr P, Chicarelli M, Tian H, Garrey R, Thomas A, Siedem CS, Welch MB, Kolakowski G, Kaus R, Burkard M, Martinson M, Chen H, Dean B, Dudley DA, Gould SE, Pacheco P, Shahidi-Latham S, Wang W, West K, Yin J, Moffat J, Schwarz JB..  (2014)  Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2..  Bioorg Med Chem Lett,  24  (12): (2635-2639).  [PMID:24813737]
64. Charoenrungruang S, Chanvorachote P, Sritularak B, Pongrakhananon V..  (2014)  Gigantol, a bibenzyl from Dendrobium draconis, inhibits the migratory behavior of non-small cell lung cancer cells..  J Nat Prod,  77  (6): (1359-1366).  [PMID:24844664]
65. Horbert R, Pinchuk B, Johannes E, Schlosser J, Schmidt D, Cappel D, Totzke F, Schächtele C, Peifer C..  (2015)  Optimization of potent DFG-in inhibitors of platelet derived growth factor receptorβ (PDGF-Rβ) guided by water thermodynamics..  J Med Chem,  58  (1): (170-182).  [PMID:25007344]
66. Dao P, Smith N, Tomkiewicz-Raulet C, Yen-Pon E, Camacho-Artacho M, Lietha D, Herbeuval JP, Coumoul X, Garbay C, Chen H..  (2015)  Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity..  J Med Chem,  58  (1): (237-251).  [PMID:25180654]
67. Carry JC, Clerc F, Minoux H, Schio L, Mauger J, Nair A, Parmantier E, Le Moigne R, Delorme C, Nicolas JP, Krick A, Abécassis PY, Crocq-Stuerga V, Pouzieux S, Delarbre L, Maignan S, Bertrand T, Bjergarde K, Ma N, Lachaud S, Guizani H, Lebel R, Doerflinger G, Monget S, Perron S, Gasse F, Angouillant-Boniface O, Filoche-Rommé B, Murer M, Gontier S, Prévost C, Monteiro ML, Combeau C..  (2015)  SAR156497, an exquisitely selective inhibitor of aurora kinases..  J Med Chem,  58  (1): (362-375).  [PMID:25369539]
68. Zhang CH, Zheng MW, Li YP, Lin XD, Huang M, Zhong L, Li GB, Zhang RJ, Lin WT, Jiao Y, Wu XA, Yang J, Xiang R, Chen LJ, Zhao YL, Cheng W, Wei YQ, Yang SY..  (2015)  Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer..  J Med Chem,  58  (9): (3957-3974).  [PMID:25835317]
69. Tan L, Akahane K, McNally R, Reyskens KM, Ficarro SB, Liu S, Herter-Sprie GS, Koyama S, Pattison MJ, Labella K, Johannessen L, Akbay EA, Wong KK, Frank DA, Marto JA, Look TA, Arthur JS, Eck MJ, Gray NS..  (2015)  Development of Selective Covalent Janus Kinase 3 Inhibitors..  J Med Chem,  58  (16): (6589-6606).  [PMID:26258521]
70. Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L..  (2015)  Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity..  Bioorg Med Chem,  23  (21): (7000-7006).  [PMID:26455654]
71. Elkamhawy A, Farag AK, Viswanath AN, Bedair TM, Leem DG, Lee KT, Pae AN, Roh EJ..  (2015)  Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking..  Bioorg Med Chem Lett,  25  (22): (5147-5154).  [PMID:26475520]
72. Aman W, Lee J, Kim M, Yang S, Jung H, Hah JM..  (2016)  Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation..  Bioorg Med Chem Lett,  26  (4): (1188-1192).  [PMID:26810260]
73. Schiemann K, Mallinger A, Wienke D, Esdar C, Poeschke O, Busch M, Rohdich F, Eccles SA, Schneider R, Raynaud FI, Czodrowski P, Musil D, Schwarz D, Urbahns K, Blagg J..  (2016)  Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore..  Bioorg Med Chem Lett,  26  (5): (1443-1451).  [PMID:26852363]
74. Kang CG, Lee HJ, Kim SH, Lee EO..  (2016)  Zerumbone Suppresses Osteopontin-Induced Cell Invasion Through Inhibiting the FAK/AKT/ROCK Pathway in Human Non-Small Cell Lung Cancer A549 Cells..  J Nat Prod,  79  (1): (156-160).  [PMID:26681550]
75. Song D, Lee M, Park CH, Ahn S, Yun CS, Lee CO, Kim HR, Hwang JY..  (2016)  Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies..  Bioorg Med Chem Lett,  26  (7): (1720-1725).  [PMID:26923695]
76. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A..  (2016)  Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors..  J Med Chem,  59  (8): (3886-3905).  [PMID:27010810]
77. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J..  (2016)  Identification of quinones as novel PIM1 kinase inhibitors..  Bioorg Med Chem Lett,  26  (13): (3187-3191).  [PMID:27173800]
78. Klaeger S, Heinzlmeir S and Wilhelm M et al.  (2017)  The target landscape of clinical kinase drugs..  Science,  358  (6367):   [PMID:29191878]
79. Chen Y, Zheng Y, Jiang Q, Qin F, Zhang Y, Fu L, He G..  (2017)  Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells..  Eur J Med Chem,  127  (997-1011).  [PMID:27839788]
80. Tassini S, Sun L, Lanko K, Crespan E, Langron E, Falchi F, Kissova M, Armijos-Rivera JI, Delang L, Mirabelli C, Neyts J, Pieroni M, Cavalli A, Costantino G, Maga G, Vergani P, Leyssen P, Radi M..  (2017)  Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases..  J Med Chem,  60  (4): (1400-1416).  [PMID:28122178]
81. Argyros O, Lougiakis N, Kouvari E, Papafotika A, Raptopoulou CP, Psycharis V, Christoforidis S, Pouli N, Marakos P, Tamvakopoulos C..  (2017)  Design and synthesis of novel 7-aminosubstituted pyrido[2,3-b]pyrazines exhibiting anti-breast cancer activity..  Eur J Med Chem,  126  (954-968).  [PMID:28006668]
82. Hoemann M, Wilson N, Argiriadi M, Banach D, Burchat A, Calderwood D, Clapham B, Cox P, Duignan DB, Konopacki D, Somal G, Vasudevan A..  (2016)  Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors..  Bioorg Med Chem Lett,  26  (22): (5562-5567).  [PMID:27789138]
83. Kang CG, Im E, Lee HJ, Lee EO..  (2017)  Plumbagin reduces osteopontin-induced invasion through inhibiting the Rho-associated kinase signaling pathway in A549 cells and suppresses osteopontin-induced lung metastasis in BalB/c mice..  Bioorg Med Chem Lett,  27  (9): (1914-1918).  [PMID:28359791]
84. Patel HM, Pawara R, Ansari A, Noolvi M, Surana S..  (2017)  Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle..  Bioorg Med Chem,  25  (10): (2713-2723).  [PMID:28366268]
85. Sugimoto Y, Sawant DB, Fisk HA, Mao L, Li C, Chettiar S, Li PK, Darby MV, Brueggemeier RW..  (2017)  Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer..  Bioorg Med Chem,  25  (7): (2156-2166).  [PMID:28259529]
86. Zhang H, Wu W, Feng C, Liu Z, Bai E, Wang X, Lei M, Cheng H, Feng H, Shi J, Wang J, Zhang Z, Jin T, Chen S, Hu S, Zhu Y..  (2017)  Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants..  Eur J Med Chem,  135  (12-23).  [PMID:28426996]
87. Patel S, Meilandt WJ, Erickson RI, Chen J, Deshmukh G, Estrada AA, Fuji RN, Gibbons P, Gustafson A, Harris SF, Imperio J, Liu W, Liu X, Liu Y, Lyssikatos JP, Ma C, Yin J, Lewcock JW, Siu M..  (2017)  Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease..  J Med Chem,  60  (19): (8083-8102).  [PMID:28929759]
88. Kahraman DC, Hanquet G, Jeanmart L, Lanners S, Šramel P, Boháč A, Cetin-Atalay R..  (2017)  Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells..  Medchemcomm,  8  (1): (81-87).  [PMID:30108693]
89. Malki WH, Gouda AM, Ali HEA, Al-Rousan R, Samaha D, Abdalla AN, Bustamante J, Abd Elmageed ZY, Ali HI..  (2018)  Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition..  Eur J Med Chem,  152  (31-52).  [PMID:29684708]
90. Liu H, Wu B, Ge Y, Huang J, Song S, Wang C, Yao J, Liu K, Li Y, Li Y, Ma X..  (2017)  Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines..  Bioorg Med Chem,  25  (24): (6313-6321).  [PMID:29102081]
91. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W..  (2018)  Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer..  Bioorg Med Chem,  26  (3): (590-602).  [PMID:29289448]
92. Assadieskandar A, Yu C, Maisonneuve P, Liu X, Chen YC, Prakash GKS, Kurinov I, Sicheri F, Zhang C..  (2018)  Effects of rigidity on the selectivity of protein kinase inhibitors..  Eur J Med Chem,  146  (519-528).  [PMID:29407977]
93. Wang Q, Liu F, Qi S, Qi Z, Yan XE, Wang B, Wang A, Wang W, Chen C, Liu X, Jiang Z, Hu Z, Wang L, Wang W, Ren T, Zhang S, Yun CH, Liu Q, Liu J..  (2018)  Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia..  Eur J Med Chem,  150  (366-384).  [PMID:29544149]
94. La Pietra V, Sartini S, Botta L, Antonelli A, Ferrari SM, Fallahi P, Moriconi A, Coviello V, Quattrini L, Ke YY, Hsing-Pang H, Da Settimo F, Novellino E, La Motta C, Marinelli L..  (2018)  Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors..  Eur J Med Chem,  150  (491-505).  [PMID:29549836]
95. He LJ, Yang DL, Li SQ, Zhang YJ, Tang Y, Lei J, Frett B, Lin HK, Li HY, Chen ZZ, Xu ZG..  (2018)  Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells..  Bioorg Med Chem,  26  (14): (3899-3908).  [PMID:29921474]
96. Pan Z, Chen Y, Liu J, Jiang Q, Yang S, Guo L, He G..  (2018)  Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy..  Eur J Med Chem,  144  (517-528).  [PMID:29288948]
97. Gao JB, Yang SJ, Yan ZR, Zhang XJ, Pu DB, Wang LX, Li XL, Zhang RH, Xiao WL..  (2018)  Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors..  J Nat Prod,  81  (4): (998-1006).  [PMID:29578342]
98. Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W..  (2018)  Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors..  Bioorg Med Chem Lett,  28  (20): (3356-3362).  [PMID:30227946]
99. Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, Huang T, Ge J, Wang L, Ren T, Wang Y, Liu J, Liu Q..  (2018)  Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor..  Eur J Med Chem,  158  (896-916).  [PMID:30253346]
100. Dodo K, Kuboki E, Shimizu T, Imamura R, Magarisawa M, Takahashi M, Tokuhiro T, Yotsumoto S, Asano K, Nakao S, Terayama N, Suda T, Tanaka M, Sodeoka M..  (2019)  Development of a Water-Soluble Indolylmaleimide Derivative IM-93 Showing Dual Inhibition of Ferroptosis and NETosis..  ACS Med Chem Lett,  10  (9): (1272-1278).  [PMID:31531196]
101. Zhang Q, Hu X, Wan G, Wang J, Li L, Wu X, Liu Z, Yu L..  (2019)  Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer..  Eur J Med Chem,  184  (111728-111728).  [PMID:31610375]
102. Choi MJ, Roh EJ, Hur W, Lee SH, Sim T, Oh CH, Lee SH, Kim JS, Yoo KH..  (2018)  Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors..  Bioorg Med Chem Lett,  28  (23-24): (3761-3765).  [PMID:30340900]
103. Narayan S, Ramisetti S, Jaiswal AS, Law BK, Singh-Pillay A, Singh P, Amin S, Sharma AK..  (2019)  ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells..  Eur J Med Chem,  161  (456-467).  [PMID:30384048]
104. Wang Y, Dou X, Jiang L, Jin H, Zhang L, Zhang L, Liu Z..  (2019)  Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia..  Eur J Med Chem,  171  (221-234).  [PMID:30925338]
105. Martínez-González S, Rodríguez-Arístegui S, Gómez de la Oliva CA, Hernández AI, González Cantalapiedra E, Varela C, García AB, Rabal O, Oyarzabal J, Bischoff JR, Klett J, Albarrán MI, Cebriá A, Ajenjo N, García-Serelde B, Gómez-Casero E, Cuadrado-Urbano M, Cebrián D, Blanco-Aparicio C, Pastor J..  (2019)  Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors..  Eur J Med Chem,  168  (87-109).  [PMID:30802730]
106. Liang X, Zang J, Li X, Tang S, Huang M, Geng M, Chou CJ, Li C, Cao Y, Xu W, Liu H, Zhang Y..  (2019)  Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies..  J Med Chem,  62  (8): (3898-3923).  [PMID:30901208]
107. Harris PA, Faucher N, George N, Eidam PM, King BW, White GV, Anderson NA, Bandyopadhyay D, Beal AM, Beneton V, Berger SB, Campobasso N, Campos S, Capriotti CA, Cox JA, Daugan A, Donche F, Fouchet MH, Finger JN, Geddes B, Gough PJ, Grondin P, Hoffman BL, Hoffman SJ, Hutchinson SE, Jeong JU, Jigorel E, Lamoureux P, Leister LK, Lich JD, Mahajan MK, Meslamani J, Mosley JE, Nagilla R, Nassau PM, Ng SL, Ouellette MT, Pasikanti KK, Potvain F, Reilly MA, Rivera EJ, Sautet S, Schaeffer MC, Sehon CA, Sun H, Thorpe JH, Totoritis RD, Ward P, Wellaway N, Wisnoski DD, Woolven JM, Bertin J, Marquis RW..  (2019)  Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase..  J Med Chem,  62  (10): (5096-5110).  [PMID:31013427]
108. Huang MR, Hsu YL, Lin TC, Cheng TJ, Li LW, Tseng YW, Chou YS, Liu JH, Pan SH, Fang JM, Wong CH..  (2019)  Structure-guided development of purine amide, hydroxamate, and amidoxime for the inhibition of non-small cell lung cancer..  Eur J Med Chem,  181  (111551-111551).  [PMID:31376567]
109. Szabadkai I, Torka R, Garamvölgyi R, Baska F, Gyulavári P, Boros S, Illyés E, Choidas A, Ullrich A, Őrfi L..  (2018)  Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors..  J Med Chem,  61  (14): (6277-6292).  [PMID:29928803]
110. Wang X, Yu C, Wang C, Ma Y, Wang T, Li Y, Huang Z, Zhou M, Sun P, Zheng J, Yang S, Fan Y, Xiang R..  (2019)  Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer..  Eur J Med Chem,  181  (111535-111535).  [PMID:31376566]
111. Zhao L, Li Y, Wang Y, Qiao Z, Miao Z, Yang J, Huang L, Tian C, Li L, Chen D, Yang S..  (2019)  Discovery of 4H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models..  J Med Chem,  62  (23): (10691-10710).  [PMID:31693351]
112. Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS..  (2017)  Discovery of a potent dual ALK and EGFR T790M inhibitor..  Eur J Med Chem,  136  (497-510).  [PMID:28528303]
113. Bronner SM, Merrick KA, Murray J, Salphati L, Moffat JG, Pang J, Sneeringer CJ, Dompe N, Cyr P, Purkey H, Boenig GL, Li J, Kolesnikov A, Larouche-Gauthier R, Lai KW, Shen X, Aubert-Nicol S, Chen YC, Cheong J, Crawford JJ, Hafner M, Haghshenas P, Jakalian A, Leclerc JP, Lim NK, O'Brien T, Plise EG, Shalan H, Sturino C, Wai J, Xiao Y, Yin J, Zhao L, Gould S, Olivero A, Heffron TP..  (2019)  Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma..  Bioorg Med Chem Lett,  29  (16): (2294-2301).  [PMID:31307887]
114. Oukoloff K, Coquelle N, Bartolini M, Naldi M, Le Guevel R, Bach S, Josselin B, Ruchaud S, Catto M, Pisani L, Denora N, Iacobazzi RM, Silman I, Sussman JL, Buron F, Colletier JP, Jean L, Routier S, Renard PY..  (2019)  Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3..  Eur J Med Chem,  168  (58-77).  [PMID:30798053]
115. Wang Q, Dai Y, Ji Y, Shi H, Guo Z, Chen D, Chen Y, Peng X, Gao Y, Wang X, Chen L, Jiang Y, Geng M, Shen J, Ai J, Xiong B..  (2019)  Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma..  Eur J Med Chem,  163  (671-689).  [PMID:30572178]
116. Jung O, Lee J, Lee YJ, Yun JM, Son YJ, Cho JY, Ryou C, Lee SY..  (2016)  Timosaponin AIII inhibits migration and invasion of A549 human non-small-cell lung cancer cells via attenuations of MMP-2 and MMP-9 by inhibitions of ERK1/2, Src/FAK and β-catenin signaling pathways..  Bioorg Med Chem Lett,  26  (16): (3963-3967).  [PMID:27422337]
117. Yao H, Xie S, Ma X, Liu J, Wu H, Lin A, Yao H, Li D, Xu S, Yang DH, Chen ZS, Xu J..  (2020)  Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer..  J Med Chem,  63  (15): (8157-8178).  [PMID:32610904]
118. Zak M,Hanan EJ,Lupardus P,Brown DG,Robinson C,Siu M,Lyssikatos JP,Romero FA,Zhao G,Kellar T,Mendonca R,Ray NC,Goodacre SC,Crackett PH,McLean N,Hurley CA,Yuen PW,Cheng YX,Liu X,Liimatta M,Kohli PB,Nonomiya J,Salmon G,Buckley G,Lloyd J,Gibbons P,Ghilardi N,Kenny JR,Johnson A.  (2019)  Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling..  Bioorg Med Chem Lett,  29  (12.0): (1522-1531).  [PMID:30981576]
119. Hamilton GL,Chen H,Deshmukh G,Eigenbrot C,Fong R,Johnson A,Kohli PB,Lupardus PJ,Liederer BM,Ramaswamy S,Wang H,Wang J,Xu Z,Zhu Y,Vucic D,Patel S.  (2019)  Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group..  Bioorg Med Chem Lett,  29  (12.0): (1497-1501).  [PMID:31000154]
120. Popow J,Arnhof H,Bader G,Berger H,Ciulli A,Covini D,Dank C,Gmaschitz T,Greb P,Karolyi-Özguer J,Koegl M,McConnell DB,Pearson M,Rieger M,Rinnenthal J,Roessler V,Schrenk A,Spina M,Steurer S,Trainor N,Traxler E,Wieshofer C,Zoephel A,Ettmayer P.  (2019)  Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions..  J Med Chem,  62  (5): (2508-2520).  [PMID:30739444]
121. Cascioferro S,Petri GL,Parrino B,Carbone D,Funel N,Bergonzini C,Mantini G,Dekker H,Geerke D,Peters GJ,Cirrincione G,Giovannetti E,Diana P.  (2020)  Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells..  Eur J Med Chem,  189  (112088-112088).  [PMID:32007666]
122. Ding X,Stasi LP,Ho MH,Zhao B,Wang H,Long K,Xu Q,Sang Y,Sun C,Hu H,Yu H,Wan Z,Wang L,Edge C,Liu Q,Li Y,Dong K,Guan X,Tattersall FD,Reith AD,Ren F.  (2018)  Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors..  Bioorg Med Chem Lett,  28  (9.0): (1615-1620).  [PMID:29588215]
123. Elwaie TA,Abbas SE,Aly EI,George RF,Ali H,Kraiouchkine N,Abdelwahed KS,Fandy TE,El Sayed KA,Abd Elmageed ZY,Ali HI.  (2020)  HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability..  J Med Chem,  63  (24.0): (15906-15945).  [PMID:33314925]
124. Chen X,Liu Y,Zhang L,Chen D,Dong Z,Zhao C,Liu Z,Xia Q,Wu J,Chen Y,Zheng X,Cai Y.  (2021)  Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer..  Eur J Med Chem,  214  (113219-113219).  [PMID:33618175]
125. Yang J,Chen K,Zhang G,Yang QY,Li YS,Huang SZ,Wang YL,Yang W,Jiang XJ,Yan HX,Zhu JQ,Xiang R,Luo YF,Li WM,Wei YQ,Li LL,Yang SY.  (2018)  Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants..  Eur J Med Chem,  143  (1148-1164).  [PMID:29133048]
126. El-Damasy AK,Jin H,Seo SH,Bang EK,Keum G.  (2020)  Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity..  Eur J Med Chem,  207  (112710-112710).  [PMID:32961435]
127. Liang X, Tang S, Liu X, Liu Y, Xu Q, Wang X, Saidahmatov A, Li C, Wang J, Zhou Y, Zhang Y, Geng M, Huang M, Liu H..  (2022)  Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors..  J Med Chem,  65  (2.0): (1243-1264).  [PMID:33586434]
128. Whitney, G S GS and 6 more authors..  (1993)  Human T and B lymphocytes express a structurally conserved focal adhesion kinase, pp125FAK..  DNA and cell biology,      [PMID:7692878]
129. Lee, S T ST, Strunk, K M KM and Spritz, R A RA..  (1993)  A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes..  Oncogene,      [PMID:8247543]
130. André, E E and Becker-André, M M..  (1993)  Expression of an N-terminally truncated form of human focal adhesion kinase in brain..  Biochemical and biophysical research communications,    (15):   [PMID:8422239]
131. Tachibana, K K and 7 more authors..  (1997)  Tyrosine phosphorylation of Crk-associated substrates by focal adhesion kinase. A putative mechanism for the integrin-mediated tyrosine phosphorylation of Crk-associated substrates..  The Journal of biological chemistry,    (14):   [PMID:9360983]
132. Matsuya, M M and 9 more authors..  (1998)  Cell adhesion kinase beta forms a complex with a new member, Hic-5, of proteins localized at focal adhesions..  The Journal of biological chemistry,    (9):   [PMID:9422762]
133. Fujita, H H and 5 more authors..  (1998)  Interaction of Hic-5, A senescence-related protein, with focal adhesion kinase..  The Journal of biological chemistry,    (9):   [PMID:9756887]
134. Schlaepfer, D D DD, Hauck, C R CR and Sieg, D J DJ..  (1999)  Signaling through focal adhesion kinase..  Progress in biophysics and molecular biology,      [PMID:10354709]
135. Miao, H H, Burnett, E E, Kinch, M M, Simon, E E and Wang, B B..  (2000)  Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation..  Nature cell biology,      [PMID:10655584]
136. Chen, R R and 8 more authors..  (2001)  Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain..  Nature cell biology,      [PMID:11331870]
137. Hecker, Timothy P TP, Grammer, J Robert JR, Gillespie, G Yancey GY, Stewart, Jerry J and Gladson, Candece L CL..  (2002)  Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples..  Cancer research,    (1):   [PMID:11980671]
138. Arold, Stefan T ST, Hoellerer, Maria K MK and Noble, Martin E M ME..  (2002)  The structural basis of localization and signaling by the focal adhesion targeting domain..  Structure (London, England : 1993),      [PMID:12005431]
139. Abbi, Smita S and 6 more authors..  (2002)  Regulation of focal adhesion kinase by a novel protein inhibitor FIP200..  Molecular biology of the cell,      [PMID:12221124]
140. Relou, Ingrid A M IA, Bax, Liane A B LA, van Rijn, Herman J M HJ and Akkerman, Jan-Willem N JW..  (2003)  Site-specific phosphorylation of platelet focal adhesion kinase by low-density lipoprotein..  The Biochemical journal,    (15):   [PMID:12387730]
141. Xia, Hong H, Nho, Richard Seonghun RS, Kahm, Judy J, Kleidon, Jill J and Henke, Craig A CA..  (2004)  Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway..  The Journal of biological chemistry,    (30):   [PMID:15166238]
142. Continolo, Silvia S and 6 more authors..  (2005)  The proto-oncogene Fgr regulates cell migration and this requires its plasma membrane localization..  Experimental cell research,    (15):   [PMID:15561106]
143. Nikolopoulos, Sotiris N SN and Giancotti, Filippo G FG..  (2005)  Netrin-integrin signaling in epithelial morphogenesis, axon guidance and vascular patterning..  Cell cycle (Georgetown, Tex.),      [PMID:15725728]
144. Golubovskaya, Vita M VM, Finch, Richard R and Cance, William G WG..  (2005)  Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53..  The Journal of biological chemistry,    (1):   [PMID:15855171]
145. Ezratty, Ellen J EJ, Partridge, Michael A MA and Gundersen, Gregg G GG..  (2005)  Microtubule-induced focal adhesion disassembly is mediated by dynamin and focal adhesion kinase..  Nature cell biology,      [PMID:15895076]
146. Nusbaum, Chad C and 75 more authors..  (2006)  DNA sequence and analysis of human chromosome 8..  Nature,    (19):   [PMID:16421571]
147. Garces, Christopher A CA, Kurenova, Elena V EV, Golubovskaya, Vita M VM and Cance, William G WG..  (2006)  Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells..  Cancer research,    (1):   [PMID:16452200]
148. Mitra, Satyajit K SK and Schlaepfer, David D DD..  (2006)  Integrin-regulated FAK-Src signaling in normal and cancer cells..  Current opinion in cell biology,      [PMID:16919435]
149. Salasznyk, Roman M RM, Klees, Robert F RF, Boskey, Adele A and Plopper, George E GE..  (2007)  Activation of FAK is necessary for the osteogenic differentiation of human mesenchymal stem cells on laminin-5..  Journal of cellular biochemistry,    (1):   [PMID:16927379]
150. Beausoleil, Sean A SA, Villén, Judit J, Gerber, Scott A SA, Rush, John J and Gygi, Steven P SP..  (2006)  A probability-based approach for high-throughput protein phosphorylation analysis and site localization..  Nature biotechnology,      [PMID:16964243]
151. Nagoshi, Yuuki Y, Yamamoto, Gou G, Irie, Tarou T and Tachikawa, Tetsuhiko T..  (2006)  Expression of FAK-related non-kinase (FRNK) coincides with morphological change in the early stage of cell adhesion..  Medical molecular morphology,      [PMID:16998626]
152. Halder, Jyotsnabaran J and 14 more authors..  (2007)  Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma..  Cancer research,    (15):   [PMID:18006843]
153. Garron, Marie-Line ML and 5 more authors..  (2008)  Structural basis for the interaction between focal adhesion kinase and CD4..  Journal of molecular biology,    (1):   [PMID:18078954]
154. Lim, Ssang-Taek ST and 9 more authors..  (2008)  Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation..  Molecular cell,    (18):   [PMID:18206965]
155. Singh, Mahendra K MK and 7 more authors..  (2008)  A novel Cas family member, HEPL, regulates FAK and cell spreading..  Molecular biology of the cell,      [PMID:18256281]
156. Semaan, Noha N, Alsaleh, Ghada G, Gottenberg, Jacques-Eric JE, Wachsmann, Dominique D and Sibilia, Jean J..  (2008)  Etk/BMX, a Btk family tyrosine kinase, and Mal contribute to the cross-talk between MyD88 and FAK pathways..  Journal of immunology (Baltimore, Md. : 1950),    (1):   [PMID:18292575]
157. Sundberg-Smith, Liisa J LJ, DiMichele, Laura A LA, Sayers, Rebecca L RL, Mack, Christopher P CP and Taylor, Joan M JM..  (2008)  The LIM protein leupaxin is enriched in smooth muscle and functions as an serum response factor cofactor to induce smooth muscle cell gene transcription..  Circulation research,    (20):   [PMID:18497331]
158. Dephoure, Noah N and 6 more authors..  (2008)  A quantitative atlas of mitotic phosphorylation..  Proceedings of the National Academy of Sciences of the United States of America,    (5):   [PMID:18669648]
159. Daub, Henrik H and 9 more authors..  (2008)  Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle..  Molecular cell,    (8):   [PMID:18691976]
160. Yamazaki, Tohru T and 5 more authors..  (2009)  EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility..  Journal of cell science,    (15):   [PMID:19118217]
161. Sachdev, Sanjay S, Bu, Yahao Y and Gelman, Irwin H IH..  (2009)  Paxillin-Y118 phosphorylation contributes to the control of Src-induced anchorage-independent growth by FAK and adhesion..  BMC cancer,    (12):   [PMID:19138410]
162. Pylayeva, Yuliya Y and 5 more authors..  (2009)  Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling..  The Journal of clinical investigation,      [PMID:19147981]
163. Oh, Min-A MA and 10 more authors..  (2009)  Specific tyrosine phosphorylation of focal adhesion kinase mediated by Fer tyrosine kinase in suspended hepatocytes..  Biochimica et biophysica acta,      [PMID:19339212]
164. Morales, Shawn A SA and 6 more authors..  (2009)  Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2)..  Investigative ophthalmology & visual science,      [PMID:19494199]
165. Tomar, Alok A and Schlaepfer, David D DD..  (2009)  Focal adhesion kinase: switching between GAPs and GEFs in the regulation of cell motility..  Current opinion in cell biology,      [PMID:19525103]
166. Tamura, Takahiko T and Chiba, Joe J..  (2009)  STEAP4 regulates focal adhesion kinase activation and CpG motifs within STEAP4 promoter region are frequently methylated in DU145, human androgen-independent prostate cancer cells..  International journal of molecular medicine,      [PMID:19787193]
167. Tanaka, Toshiyuki T, Moriwaki, Kazumasa K, Murata, Shinsuke S and Miyasaka, Masayuki M..  (2010)  LIM domain-containing adaptor, leupaxin, localizes in focal adhesion and suppresses the integrin-induced tyrosine phosphorylation of paxillin..  Cancer science,      [PMID:19917054]
168. Stewart, Cameron R CR and 13 more authors..  (2010)  CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer..  Nature immunology,      [PMID:20037584]
169. and Guan, Jun-Lin JL..  (2010)  Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer..  IUBMB life,      [PMID:20101634]
170. Cai, Guo-qiang GQ and 7 more authors..  (2010)  Downregulation of FAK-related non-kinase mediates the migratory phenotype of human fibrotic lung fibroblasts..  Experimental cell research,    (15):   [PMID:20109444]
171. Nagano, Makoto M and 5 more authors..  (2010)  ZF21 protein regulates cell adhesion and motility..  The Journal of biological chemistry,    (2):   [PMID:20439989]
172. Sun, Haihao H, Pisle, Stephen S, Gardner, Erin R ER and Figg, William D WD..  (2010)  Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models..  Cancer biology & therapy,    (1):   [PMID:20495381]
173. Golubovskaya, Vita M VM and Cance, William W..  (2010)  Focal adhesion kinase and p53 signal transduction pathways in cancer..  Frontiers in bioscience (Landmark edition),    (1):   [PMID:20515733]
174. Chatzizacharias, Nikolaos A NA, Kouraklis, Gregory P GP and Theocharis, Stamatios E SE..  (2010)  The role of focal adhesion kinase in early development..  Histology and histopathology,      [PMID:20552554]
175. Hall, Emily H EH and 5 more authors..  (2010)  Comprehensive analysis of phosphorylation sites in Tensin1 reveals regulation by p38MAPK..  Molecular & cellular proteomics : MCP,      [PMID:20798394]
176. Plaza-Menacho, Iván I and 9 more authors..  (2011)  Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism..  The Journal of biological chemistry,    (13):   [PMID:21454698]
177. Zhou, Houjiang H and 6 more authors..  (2013)  Toward a comprehensive characterization of a human cancer cell phosphoproteome..  Journal of proteome research,    (4):   [PMID:23186163]
178. Armacki, M M and 8 more authors..  (2014)  A novel splice variant of calcium and integrin-binding protein 1 mediates protein kinase D2-stimulated tumour growth by regulating angiogenesis..  Oncogene,    (27):   [PMID:23503467]
179. Zhu, Mei M and 7 more authors..  (2013)  MISP is a novel Plk1 substrate required for proper spindle orientation and mitotic progression..  The Journal of cell biology,    (18):   [PMID:23509069]
180. Rui, Yan-Ning YN and 7 more authors..  (2017)  The Intracranial Aneurysm Gene THSD1 Connects Endosome Dynamics to Nascent Focal Adhesion Assembly..  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,      [PMID:29069646]
181. Wallmeier, Julia and 29 more authors..  (2019)  De Novo Mutations in FOXJ1 Result in a Motile Ciliopathy with Hydrocephalus and Randomization of Left/Right Body Asymmetry..  American journal of human genetics,    (7):   [PMID:31630787]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.